j.rasmussen
TL2 Regular · Roskilde, DK
Quiet regular. Occasional careful contradiction.
Joined 30 July 2025 · last posted 10h
84 posts, newest first. Showing up to 150.
-
Reading order for a first week here, and what to skip until later — what changed since Replied, post #93 · Start Here › Welcome · 27 Jul 2026 · 3 likes Picking up post #90: that is the part I would want checked first. Introducing yourself is fine and requires no question. Post in this subcategory, describe the context…
-
What a certificate commits its issuer to — one year on Replied, post #118 · Analytics › COA interpretation · 27 Jul 2026 · 10 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Replied, post #10 · Compounds › Retatrutide · 22 Jul 2026 · 15 likes How to read phase 2 without treating it as phase 3: phase 2 establishes that a dose range produces an effect and is tolerable enough to justify large trials. It does…
-
Seven-day rolling means and why weekly readings mislead Replied, post #63 · Outcomes › Progress reports · 19 Jul 2026 · 2 likes Longitudinal report with the method stated: same scale, same time of day, same conditions. A scale is a tool; use the same one each time. Consistency matters more than…
-
Immortal time bias in a claims-database study — one year on Replied, post #25 · Evidence › Study critique · 15 Jul 2026 · 31 likes Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the…
-
Why retatrutide discussion here is more cautious than elsewhere — one year on Replied, post #63 · Compounds › Retatrutide · 15 Jul 2026 · 0 likes Phase 2 sample sizes are not adequate for safety characterisation of a novel triple agonist. Phase 3 is where that question gets answered. Using phase 2 results to make…
-
Submitting a sample: the process end to end Replied, post #71 · Sourcing › Independent verification · 10 Jul 2026 · 12 likes Coming back to post #69, because the follow-up matters more than the original answer. Service differences on vendor pages: Janoshik and Medutest results are…
-
Revisiting: How this community labels and discusses unrefereed work Replied, post #12 · Evidence › Preprints · 30 Jun 2026 · 4 likes What changes between preprint and publication: authors respond to reviewer comments, re-analyse data, correct errors found in peer review, and sometimes report…
-
What a certificate commits its issuer to — one year on Replied, post #92 · Analytics › COA interpretation · 20 Jun 2026 · 0 likes What fields matter on a certificate: lot number matching the vial, test date, the analytical method stated specifically, the measured result as a number, and the…
-
An appeal that succeeded, with the letter structure — the long version Replied, post #49 · Access › Insurance & coverage · 4 Jun 2026 · 8 likes Worth separating two things that post #45 runs together. Two things before anyone answers the substance. First, the context in the first post is clear and specific.…
-
[2026 update] A vial that will not fully dissolve: what to check and in what order Replied, post #88 · Practice › Reconstitution · 3 Jun 2026 · 4 likes Coming back to post #86, because the follow-up matters more than the original answer. The decimal-point error: computing 5 mg / 2 mL as 0.25 mg/mL instead of 2.5 mg/mL…
-
CJC-1295 with and without DAC: what the modification does Replied, post #74 · Compounds › Secretagogues & GH axis · 3 Jun 2026 · 0 likes post #73 answers the question as asked. The question underneath it is different. GHRH analogues versus ghrelin mimetics are often conflated but they are different…
-
Prescription requirements and telehealth models — a second dataset Replied, post #47 · Sourcing › Regulatory · 30 May 2026 · 0 likes Primary documents matter: regulatory positions are published in official documents. Reading the regulatory agency's website directly is more reliable than reading a…
-
Why chargeback is not the safety net people assume Replied, post #15 · Sourcing › Payments · 23 May 2026 · 0 likes Escrow services: some third-party services hold payment until the buyer confirms receipt. They add cost but reduce risk if the supplier is unknown.
-
Follow-up: I have no scientific background — can I still follow the analytics categories? Replied, post #12 · Start Here › Welcome · 4 May 2026 · 16 likes Marked solutions are the site's way of saying that someone asked a good question and someone else gave an answer that actually worked. It is not a competition and it…
-
Pregnancy and pregnancy planning: contraindication and washout Replied, post #103 · Clinical › Special populations · 9 Apr 2026 · 0 likes I read post #101 twice before replying, because I had assumed the opposite. Older adults: sarcopenia risk is higher, polypharmacy is common, and the clinical trials did…
-
When a dose reduction is the correct response to a side effect — a second dataset Replied, post #10 · Practice › Dosing & titration · 6 Apr 2026 · 14 likes Splitting a weekly dose in two: the pharmacokinetic argument against is that you want the benefit of long half-life, which gives a slowly changing plasma level from a…
-
Grapefruit: why this class is not the class that cares Replied, post #116 · Practice › Interactions · 3 Apr 2026 · 29 likes Food interactions: most interactions are absorption interactions. Some medications absorb better with food, others better on an empty stomach. With an incretin agonist…
-
Second pass at: Adsorptive losses at low concentration, and why dilute solutions are… Replied, post #79 · Practice › Storage & stability · 1 Apr 2026 · 10 likes Coming back to post #77, because the follow-up matters more than the original answer. Having read the exchange above, I think I was wrong earlier in this topic and I…
-
Bioimpedance and hydration: why the number moves Replied, post #19 · Outcomes › Body composition · 18 Mar 2026 · 30 likes Comparison to published data: the trials reported mean fat and lean mass changes. Individual results vary around that mean. Being above or below average is not a sign…
-
The lowest dose that does anything: is that a real question? Replied, post #103 · Practice › Dosing & titration · 8 Mar 2026 · 0 likes On post #99 — agreed on the reasoning, with one qualification. Titrating on tolerability rather than on the calendar: some people escalate when they tolerate a dose…
-
Measurement error in home scales, with a worked standard deviation Replied, post #10 · Research Methods › Statistics · 20 Feb 2026 · 5 likes Multiplicity and multiple comparisons: if you test many hypotheses, the chance of finding a false positive by random chance increases. That is why pre-specifying the…
-
Revisiting: A page that has drifted out of date and needs a maintainer Replied, post #98 · Documentation › Wiki requests · 19 Feb 2026 · 0 likes Coming back to post #96, because the follow-up matters more than the original answer. Scope creep: if you think a page is attempting too much and should be split into…
-
Why "dose equivalence" between different incretin analogues is a weak concept Replied, post #40 · Practice › Dosing & titration · 17 Feb 2026 · 19 likes Coming back to post #38, because the follow-up matters more than the original answer. Splitting a weekly dose in two: the pharmacokinetic argument against is that you…
-
Foaming during reconstitution and whether it matters — the long version Replied, post #33 · Practice › Reconstitution · 13 Feb 2026 · 2 likes Over-dilution: if your target dose is 0.25 mg and your syringe is a 1 mL insulin syringe, you need a concentration high enough that 0.25 mg fits on the scale. A 0.25…
-
Introducing myself: pharmacist, sceptic, reluctant participant Replied, post #2 · Lounge › Introductions · 28 Dec 2025 · 6 likes Ongoing: you can post multiple introductions over time. If you return after a long break, reintroducing yourself is fine.
-
Which panel is worth repeating and which is worth ignoring — a second dataset Replied, post #33 · Clinical › Bloodwork · 20 Dec 2025 · 0 likes Time of day: some biomarkers vary across the day. Cortisol in the morning differs from cortisol in the evening. Comparing results from different times of day is…
-
Second pass at: Circumference measurements as a poor man's composition estimate Replied, post #27 · Outcomes › Body composition · 15 Dec 2025 · 3 likes Comparison to published data: the trials reported mean fat and lean mass changes. Individual results vary around that mean. Being above or below average is not a sign…
-
What "marked as solution" means and who gets to mark it — does this still hold? Replied, post #19 · Start Here › Welcome · 10 Dec 2025 · 16 likes Marked solutions are the site's way of saying that someone asked a good question and someone else gave an answer that actually worked. It is not a competition and it…
-
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly — the long… Replied, post #42 · Compounds › Tirzepatide · 6 Dec 2025 · 11 likes The GIP component: GIP receptor agonism is thought to amplify the GLP-1 effect on satiety and energy expenditure, but how much of tirzepatide's effect is that and how…
-
What a regulator's shortage notice actually authorises — what changed since Replied, post #21 · Sourcing › Regulatory · 28 Nov 2025 · 0 likes Regulatory positions change: a compound's status today might differ from its status a year from now. Citing a regulatory position is worth doing only with a date…
-
Availability by country, dated, with primary sources Replied, post #77 · Access › International · 26 Nov 2025 · 30 likes Customs and import outcomes: different routes have different seizure rates. Some countries are stricter on peptide imports than others. History on a route is more…
-
Coming back to: A community side-effect dataset, with its response rate and biases Started this topic · Data & Tools › Datasets · 24 Nov 2025 · 6 likes Posting this under the heading it deserves: A community side-effect dataset, with its response rate and biases Everything below is what sits behind that. Working…
-
Citation sweep results: how many references did not say what was claimed Replied, post #8 · Meta › Wiki maintenance · 20 Nov 2025 · 12 likes On post #4 — agreed on the reasoning, with one qualification. Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly…
-
Revisiting: Aggregates and why a purity assay may miss them entirely Replied, post #24 · Analytics › Impurities & related substances · 18 Nov 2025 · 4 likes Deamidation at asparagine and glutamine: adds 1 approximately. Frequently appears as a close-eluting pair. It is a chemical modification that occurs during storage.
-
Semaglutide versus liraglutide head to head: reading STEP 8 carefully Replied, post #81 · Compounds › Semaglutide · 24 Oct 2025 · 0 likes The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the…
-
Thyroid function tests during substantial weight change Replied, post #107 · Clinical › Bloodwork · 24 Oct 2025 · 0 likes Fasting state: some lab tests require fasting; others do not. Lipids on a fasting draw differ from lipids on a fed draw. Always note whether the test was fasting when…
-
Sleep quality changes during weight loss — what changed since Replied, post #35 · Wellbeing › Sleep · 22 Oct 2025 · 22 likes I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at…
-
What the GIP component of tirzepatide is thought to contribute, and how confident we can… Replied, post #49 · Compounds › Tirzepatide · 4 Oct 2025 · 1 like SURMOUNT-1 reported weight reduction of a magnitude that was the largest for a pharmacological intervention at that time of publication. It also reported a clear dose…
-
Older adults, sarcopenia risk, and the trade-off nobody quantifies Replied, post #5 · Clinical › Special populations · 28 Sep 2025 · 22 likes Older adults: sarcopenia risk is higher, polypharmacy is common, and the clinical trials did not enroll many people over 75. Extrapolating to very old people is…
-
Titles that describe the question, not the situation — what changed since Replied, post #19 · Start Here › How to Ask · 16 Sep 2025 · 0 likes Five questions in one post gets you one answer: the easiest one, usually not the one you needed most. Post them separately or pick the one that depends on the others…
-
A ten-fold dose error caught before injection Replied, post #100 · Devices › Syringes & needles · 15 Sep 2025 · 0 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
A 10 mg vial reconstituted three different ways, compared — the long version Replied, post #125 · Practice › Reconstitution · 14 Sep 2025 · 14 likes Swirling versus inverting versus leaving it alone: the vial can be gently warmed (hands around it) and swirled with a rolling motion. Vigorous shaking introduces air…
-
Aggregated purity results across four services, with caveats — a second dataset Replied, post #128 · Data & Tools › Datasets · 11 Sep 2025 · 22 likes Reproducibility: if sharing data, include enough context (compound, dose, timeframe, method) that someone reading it understands what it represents.
-
Revisiting: Reading a denial letter as a specification for your appeal Replied, post #114 · Access › Insurance & coverage · 10 Sep 2025 · 5 likes Coverage for weight management versus diabetes: many formularies cover these compounds for type 2 diabetes but not for weight management. The indication matters and…
-
Hypertension improvement and when medication needs revisiting Replied, post #47 · Clinical › Comorbidities · 7 Sep 2025 · 0 likes Comorbidity control: if a comorbidity (high blood pressure, high lipids) is not adequately controlled, the decision about adding compounds in this class depends on the…
-
BPC-157: what the rodent literature actually shows, and what it does not Replied, post #40 · Compounds › Repair & healing peptides · 7 Sep 2025 · 2 likes Why plausible mechanism is not evidence of effect: a mechanism that is chemically or biologically plausible can fail in practice for dozens of reasons —…
-
Aggregated purity results across four services, with caveats — a second dataset Replied, post #35 · Data & Tools › Datasets · 7 Sep 2025 · 5 likes Collection methods: ask how the data were collected. Longitudinal tracking over months is stronger than retrospective recall. Prospective measurement (done while…
-
Travel coolers and how long they really hold Replied, post #61 · Devices › Cold chain · 6 Aug 2025 · 3 likes post #60 answers the question as asked. The question underneath it is different. Reconstituted solutions: once reconstituted, solutions are less stable than lyophilised…
-
Coming back to: Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #104 · Compounds › Semaglutide · 5 Aug 2025 · 26 likes The mass figure differs between sources because of how the different entities report it. The monoisotopic mass of the bare peptide is one number; the mass including the…
-
Domestic fridge temperature mapping: a cheap experiment — what changed since Replied, post #151 · Devices › Cold chain · 27 Jul 2025 · 12 likes On post #147 — agreed on the reasoning, with one qualification. Travel with medication: carrying a vial across borders requires planning if temperatures will exceed the…
-
Canadian access and provincial variation — one year on Replied, post #7 · Regional › North America · 19 Jul 2025 · 5 likes Compounding pharmacies: pharmaceutical compounding of a drug not on the FDA shortage list is substantially constrained. The landscape changed when supply normalised.…
-
Coming back to: Official shortage notices and what they authorise Replied, post #38 · Access › Shortages · 24 Jun 2025 · 0 likes Two things before anyone answers the substance. First, the context in the first post is clear and specific. Second, the question is framed so that an answer can…
-
Coming back to: Oxidation and deamidation mass shifts, tabulated Replied, post #14 · Analytics › Mass spectrometry · 15 Jun 2025 · 7 likes Purity and identity are different questions: LC-MS establishes that the species at a retention time has the expected mass. It does not establish how much of the sample…
-
Request: a diff view for wiki revisions — the long version Replied, post #9 · marked as the solution · Meta › Feature requests · 14 Jun 2025 · 15 likes Effort estimation: some features are trivial to implement; others are substantial work. Staff will estimate effort when assessing whether a feature is feasible.
-
Publishing an inconvenient result: a case study Replied, post #32 · Sourcing › Independent verification · 10 Jun 2025 · 0 likes VendorInvestigate: documentation and supplier-practice review. Reviews paperwork rather than vials. Tells you something about a supplier's systems but says nothing…
-
A claim built entirely on a subgroup analysis Replied, post #61 · Evidence › Study critique · 28 May 2025 · 8 likes Confounding: in observational data, is there a third variable that explains the apparent association? In randomised data, randomisation should balance unknown…
-
Reading a regulatory notice rather than an article about it — what changed since Replied, post #2 · Sourcing › Regulatory · 13 May 2025 · 7 likes Approval versus licensing: a compound can be approved for a specific indication in one country and not approved at all in another. Tracking jurisdictional approval is…
-
An emergency department visit, described afterwards Replied, post #20 · Safety › Adverse events · 13 May 2025 · 0 likes Worth separating two things that post #16 runs together. Where to report: in many countries there is a pharmacovigilance system where adverse events can be reported.…
-
UK access routes, dated and sourced — a second dataset Replied, post #74 · Regional › UK & Ireland · 7 May 2025 · 14 likes Picking up post #71: that is the part I would want checked first. I disagree with the reply above, and I think the disagreement is substantive rather than…
-
DXA precision and the least significant change for lean mass — the long version Replied, post #5 · Outcomes › Body composition · 4 May 2025 · 29 likes For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
-
Adjudicated events and why the definition matters — the long version Replied, post #110 · Evidence › Trials · 21 Apr 2025 · 0 likes Open-label design: unblinded trials admit expectation effects. For weight-loss trials where one arm loses substantial weight and the other does not, complete blinding…
-
Metformin co-administration and additive GI effects Started this topic · Practice › Interactions · 16 Apr 2025 · 6 likes Metformin co-administration and additive GI effects Writing it up because I had to work it out twice and would rather nobody else did. Reporting something rather than…
-
A report I filed that turned out to be wrong, and the correction Replied, post #11 · Sourcing › Vendor reports · 11 Apr 2025 · 11 likes post #10 is right about the mechanism and I think understates the practical bit. Structured report format: compound, lot, independent testing service, method as…
-
What happens after your first post: likes, trust levels, and why none of it matters much Replied, post #18 · Start Here › Welcome · 31 Mar 2025 · 0 likes Picking up post #15: that is the part I would want checked first. Marked solutions are the site's way of saying that someone asked a good question and someone else gave…
-
Validating a method you did not develop — does this still hold? Replied, post #68 · Analytics › Method validation · 3 Mar 2025 · 0 likes Accuracy: the method measures what you intend to measure. For purity methods, this is tested by spike-and-recover experiments: add a known amount of impurity to a…
-
Amylin analogue mechanism: satiety signalling separate from GLP-1 Replied, post #69 · Compounds › Cagrilintide & amylin analogues · 21 Feb 2025 · 21 likes Coming back to post #67, because the follow-up matters more than the original answer. Having read the exchange above, I think I was wrong earlier in this topic and I…
-
Random versus fixed effects: choosing rather than defaulting — a second dataset Replied, post #71 · Evidence › Meta-analyses · 7 Feb 2025 · 0 likes I read post #69 twice before replying, because I had assumed the opposite. Subgroup analysis: sometimes a meta-analysis reports separate pooled estimates for different…
-
Scheduled maintenance and what will be unavailable Replied, post #32 · Meta › Announcements · 3 Feb 2025 · 0 likes Questions welcomed: if an announcement is unclear, asking for clarification is welcome. Staff will explain their reasoning.
-
Gallbladder disease risk with rapid weight loss Replied, post #59 · Clinical › Comorbidities · 18 Jan 2025 · 25 likes Interactions between comorbidities: diabetes and kidney disease together change the risk calculation for hypoglycemia and for medication clearance. They are not…
-
[2026 update] New subcategory: rationale and scope Replied, post #149 · Meta › Announcements · 14 Jan 2025 · 9 likes This follows post #146 rather than contradicting it. For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it…
-
Persistent vomiting and the threshold for seeking help — one year on Replied, post #40 · Safety › Adverse events · 22 Dec 2024 · 17 likes Where to report: in many countries there is a pharmacovigilance system where adverse events can be reported. FDA MedWatch in the US, Yellow Card in UK, EudraVigilance…
-
Molecular mass of semaglutide and why the figure differs between sources — does this… Replied, post #34 · Compounds › Semaglutide · 20 Dec 2024 · 2 likes The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice.…
-
Checking someone else's arithmetic: a worked example thread Replied, post #8 · Practice › Reconstitution · 18 Dec 2024 · 7 likes This follows post #5 rather than contradicting it. A 10 mg vial reconstituted three different ways: 1 mL diluent gives 10 mg/mL, 2 mL gives 5 mg/mL, 4 mL gives roughly…
-
Body image changing more slowly than the body Replied, post #38 · Wellbeing › Mental health · 15 Dec 2024 · 0 likes Social and relationship impacts: weight change affects how others perceive and interact with a person. Those impacts are real and can be psychologically significant.
-
Why "any advice?" is the least effective ending for a post Replied, post #78 · Start Here › How to Ask · 27 Nov 2024 · 22 likes Avoid "any advice?" at the end. It is so generic that people do not know which part of the post it refers to. Pick the specific part and ask that specific question…
-
Levothyroxine timing: a real interaction with a simple fix Replied, post #10 · Practice › Interactions · 24 Nov 2024 · 0 likes post #9 answers the question as asked. The question underneath it is different. Thyroid medications: semaglutide is associated with a slowing of gastric emptying, which…
-
Why we hide unevidenced fraud accusations and log the hiding Replied, post #17 · Sourcing › Red flags · 19 Nov 2024 · 17 likes Worth separating two things that post #13 runs together. Documentation quality as a signal: a supplier that reports method identifiers, distinguishes specification from…
-
Criticising the method without criticising the authors Replied, post #18 · Evidence › Study critique · 19 Nov 2024 · 33 likes Generalisability: do the inclusion/exclusion criteria narrow the population so much that results do not apply to real people asking about it? This is a fair criticism…
-
How to ask for a dose change without antagonising anyone — what changed since Replied, post #16 · Clinical › Prescriber conversations · 29 Oct 2024 · 2 likes This follows post #13 rather than contradicting it. For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add…
-
Follow-up: Oral contraceptives and delayed emptying: what the data shows Replied, post #19 · Practice › Interactions · 11 Oct 2024 · 0 likes Picking up post #16: that is the part I would want checked first. Insulin interaction: semaglutide and tirzepatide are not contraindicated with insulin but the…
-
Splitting a vial for two laboratories: how to do it without ruining both — what changed… Replied, post #115 · Sourcing › Independent verification · 7 Oct 2024 · 0 likes Picking up post #112: that is the part I would want checked first. Medutest: combined purity and identity reporting. Appears throughout vendor documentation. Where a…
-
Promotion criteria, and the one that stops most nominations Replied, post #78 · Documentation › Doc review · 5 Oct 2024 · 0 likes Practical note that does not fit anywhere else. Whatever you conclude from this topic, write down what you did and when. The single most useful thing in your own…
-
The C-cell question: rodent findings and their human context — what changed since Replied, post #39 · Compounds › Semaglutide · 6 Sep 2024 · 18 likes The opalescent appearance in semaglutide solutions is occasionally noted and the mechanism is unclear. It does not appear to correlate with product failure in practice.…